X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs IPCA LABS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES IPCA LABS DIVIS LABORATORIES/
IPCA LABS
 
P/E (TTM) x 18.1 27.7 65.6% View Chart
P/BV x 3.9 2.1 185.1% View Chart
Dividend Yield % 1.6 0.2 650.8%  

Financials

 DIVIS LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
IPCA LABS
Mar-17
DIVIS LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,484643 386.3%   
Low Rs918503 182.6%   
Sales per share (Unadj.) Rs142.3254.4 55.9%  
Earnings per share (Unadj.) Rs41.916.1 260.6%  
Cash flow per share (Unadj.) Rs46.329.8 155.6%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %0.60.2 336.8%  
Book value per share (Unadj.) Rs161.5194.6 83.0%  
Shares outstanding (eoy) m265.47126.20 210.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.02.3 531.0%   
Avg P/E ratio x40.635.7 113.9%  
P/CF ratio (eoy) x36.719.2 190.8%  
Price / Book Value ratio x10.52.9 357.6%  
Dividend payout %23.96.2 383.7%   
Avg Mkt Cap Rs m451,52572,300 624.5%   
No. of employees `0003.713.3 27.9%   
Total wages/salary Rs m3,6496,960 52.4%   
Avg. sales/employee Rs Th10,184.42,413.5 422.0%   
Avg. wages/employee Rs Th984.1523.2 188.1%   
Avg. net profit/employee Rs Th2,998.5152.4 1,966.9%   
INCOME DATA
Net Sales Rs m37,76432,106 117.6%  
Other income Rs m848226 375.9%   
Total revenues Rs m38,61232,332 119.4%   
Gross profit Rs m14,1384,448 317.9%  
Depreciation Rs m1,1821,730 68.3%   
Interest Rs m23241 9.6%   
Profit before tax Rs m13,7812,703 509.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,662675 394.3%   
Profit after tax Rs m11,1192,028 548.2%  
Gross profit margin %37.413.9 270.2%  
Effective tax rate %19.325.0 77.3%   
Net profit margin %29.46.3 466.1%  
BALANCE SHEET DATA
Current assets Rs m30,94717,340 178.5%   
Current liabilities Rs m5,1959,559 54.3%   
Net working cap to sales %68.224.2 281.4%  
Current ratio x6.01.8 328.4%  
Inventory Days Days117100 116.4%  
Debtors Days Days8557 149.7%  
Net fixed assets Rs m17,02720,779 81.9%   
Share capital Rs m531252 210.3%   
"Free" reserves Rs m42,34124,499 172.8%   
Net worth Rs m42,87724,553 174.6%   
Long term debt Rs m53,517 0.1%   
Total assets Rs m49,68439,595 125.5%  
Interest coverage x595.012.2 4,866.7%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.80.8 93.7%   
Return on assets %22.45.7 391.4%  
Return on equity %25.98.3 313.9%  
Return on capital %32.210.5 306.9%  
Exports to sales %85.348.6 175.3%   
Imports to sales %22.914.2 161.0%   
Exports (fob) Rs m32,19815,617 206.2%   
Imports (cif) Rs m8,6544,571 189.3%   
Fx inflow Rs m32,27015,617 206.6%   
Fx outflow Rs m8,7755,828 150.6%   
Net fx Rs m23,4969,790 240.0%   
CASH FLOW
From Operations Rs m10,3792,764 375.5%  
From Investments Rs m-4,135-1,432 288.8%  
From Financial Activity Rs m-6,241-1,591 392.2%  
Net Cashflow Rs m3-259 -1.3%  

Share Holding

Indian Promoters % 52.0 45.9 113.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 11.4 103.5%  
FIIs % 19.0 25.3 75.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.4 98.9%  
Shareholders   31,796 36,892 86.2%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS